Bessemer Group
DAWN

Bessemer Group’s Day One Biopharmaceuticals DAWN Stock Holding History

Bessemer Group’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-85
Closed -$1K – 2500
2024
Q3 		$1K Buy
+85
New +$1.21K ﹤0.01% 2375

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Bessemer Group's DAWN Position: Q4 2024 in Review

Bessemer Group sold out of Day One Biopharmaceuticals (DAWN) in Q4 2024, closing a stake of 85 shares — an estimated $1K sold.

Bessemer Group first reported a position in DAWN in Q3 2024 and held it in 1 quarter. The position peaked at $1K in Q3 2024. 164 funds tracked by Wall St. Rank hold DAWN as of Q4 2024.

  • Bessemer Group reported no remaining Day One Biopharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Bessemer Group sold 85 Day One Biopharmaceuticals shares in Q4 2024, an estimated $1K.
  • Bessemer Group first reported a position in Day One Biopharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Bessemer Group's Day One Biopharmaceuticals position peaked at $1K in Q3 2024.
  • 164 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.